SAN FRANCISCO — Both pediatric and adult patients with type 1 diabetes (T1D) had favorable outcomes for glycemic control with use of the Omnipod® Insulin Management System, according to real-world study data presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019, in San Francisco, California.
Glucose management indicator (GMI), a new term for estimating hemoglobin A1C from CGM data, is intended to provide information about glucose management for patients with diabetes. This large real-world cohort study assessed GMI and glycemic metrics of pediatric, adolescent, and adult patients with T1D using data from the Omnipod Insulin Management System (Insulet Corp, Acton, MA), real-time CGM (Dexcom, San Diego, CA), and data management system (Glooko, Mountain View, CA). Usage data from January 2015 to September 2018 were matched using serial numbers of devices to a second database of self-reported demographic information and deidentified.
CGM data from participants using CGM for more than 50% of days over ≥3 months of system use were analyzed (N = 1838). Glycemic profiles and insulin use for participants were stratified by age: <6 years (n = 94), 6 to <12 years (n = 410), 12 to <18 years (n = 316), and ≥18 years (n = 1018). GMI across age groups was 7.8%, 7.5%, 7.4%, and 7.0%, respectively. The corresponding estimations for hemoglobin A1c were 8.2%, 7.7%, 7.6%, and 7.0%, respectively.
Percent time in range (70-180 mg/dL) was 48.8%, 56.7%, 58.1%, and 66.4%, respectively, for the <6 year age group, 6 to <12 year age group, 12 to <18 year age group, and ≥18 year age group.
The study investigators concluded that the findings from this study “provide valuable insights to GMI and glycemic metrics, and demonstrate that the use of tubeless insulin pump with CGM is associated with favorable glycemic control when compared to large national registries such as the T1D Exchange.”
This study was supported by Insulet Corporation.
Layne JE, Jantz J, Zheng Y, He J, Benjamin E, Ly TT. Glucose management indicator results from real-world data of 1,838 patients with type 1 diabetes using the Omnipod® Insulin Management System with continuous glucose monitoring and cloud-based data management. Presented at: American Diabetes Association 79th Scientific Sessions; June 7-11, 2019; San Francisco, CA. Poster 1055-P.